Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Elżbieta Iskierka‐Jazdzewska(Copernicus Memorial Hospital), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Huilai Zhang(Shanxi Medical University), Francesca Lim(Singapore General Hospital), Matthew Reaney(Sanofi (United Kingdom)), Sabarish Ayyappan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Srikanth Ambati(Regeneron (United States)), Tran‐Der Tan(Koo Foundation Sun Yat-Sen Cancer Center), Hesham Mohamed(Bristol-Myers Squibb (United States)), H. Miles Prince(Peter MacCallum Cancer Centre), Lei Chi(Regeneron (United States)), Cecilia Carpio(Universitat Autònoma de Barcelona), Isidro Jarque(Hospital Universitari i Politècnic La Fe), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Won Seog Kim(Samsung Medical Center), Sung Yong Oh(Korea University Medical Center), Junning Cao(Fudan University Shanghai Cancer Center), Benoît Tessoulin(Centre Hospitalier Universitaire de Nantes), Tadeusz Robak(Medical University of Lodz), Cristina Ivanescu, Mingzhi Zhang(Chinese Academy of Sciences), Tae Min Kim(Seoul National University Hospital), Jingjin Li(Inner Mongolia Agricultural University), Michelle Poon(National University Hospital), James Harnett(Regeneron (United States)), Aafia Chaudhry(Regeneron (United States)), Antonio Gutiérrez(Hospital Universitario Son Dureta)
Cited by 3
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907